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Novel coronavirus disease (COVID-19) caused by 
severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) is characterized as a pandemic by WHO. 
Differential expression analysis takes the normalized read 
count data and performing statistical analysis to discover 
quantitative changes in expression levels between 
experimental groups and give DEGs from functional 
genomics experiments which depend on the scale and 
intent of the experiment. Some commonly used 
technologies are real-time PCR, microarray analysis, 
next-generation sequencing, and RNA-seq. Our study 
aimed to look for the differential expressed genes in viral 
respiratory tract infection. Furthermore, we wanted to 
consider these genes expression to be noticed during the 
current pandemic infection SARS-CoV-2 patients as 
most of the viral respiratory tract infections have the same 
pathogenesis and disease pattern. These genes were found 
to be up-regulated in the study during the viral respiratory 
tract infection and which might be helpful in 
understanding the pathogenesis, disease management, 
drug, and vaccines developed for the current COVID-19 
infection. Our study is a bioinformatics based analysis on 
the NCBI GSE68310 dataset, which is a microarray 
dataset for different respiratory viral infections. We got 
different down and up-regulated DEGs through limma 
package utilizing GEO2R of the NCBI and P<0.05, and 
log fold change (FC)> one was used as the cut-off criteria. 
α-Defensins rectify acute lung injury (ALI) by LRP-
mediated loss of capillary-epithelial barrier function, 
implying a probable new method to intervention (1). 
Defensins have an effective immunomodulatory effect 
that can modify inborn and flexible immune reactions to 
viral infection. There are a few cases where data shows 
paradoxical desertion from defensin neutralization or 
development of viral infection. (2). LILRA3 role is 
currently unidentified and can cohere human leukocyte 
antigen (HLA) class I. Consequently, assuming that it 
excretes, then the LILRA3 might weaken the interaction 
of membrane-bound LILRs (such as LILRB1, an 
inhibitory receptor expressed on effector and 
memory CD8 T cells) with their HLA ligands, hence 
tempering immune reactions and prompting vulnerability 
to disease. (3,4,5). LILRA3 was also reported up-
regulated in the PBMCs from patients with SARS. 
Concentrating this gene in SAR-COV-2 patients will 
allow for new approaches for producing novel diagnostics 
and treatments for this new lethal disease (6). IGLL1 gene 
encodes one of the surrogate light chain subunits and 
belongs to the immunoglobulin gene superfamily. This 
gene does not go through rearrange. Alterations in this 
gene can lead to B cell deficiency and 
Agammaglobulinemia (7). Up until now, the 7 Primary 
Antibody Deficiencies (PAD) patients with the COVID-
19 virus have been found. Five of those seven have had 
Common Variable Immune Deficiencies (CVIDs), two of 
them have been affected with Agammaglobulinemia, one 
with X-linked Agammaglobulinemia (XLA) and one with 
Autosomal Recessive Agammaglobulinemia (ARA) (8). 
Examining this gene in COVID patients can assist in 
finding probable signs of new therapeutic targets. 
Numerous RPs work with viral mRNA and proteins to 
take part in viral protein biosynthesis and control the 
imitation and contamination of viruses in host cells. This 
gene expression needs to be checked during COVID-19 
because many of the communications are important for 
viral conversion and imitation, which encourage viral 
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infection and growth. The antiviral approach established 
on RPs will be used as models for additional studies (9). 
Over the past few decades, it has been highly valued that 
the enzyme phospholipase A2 (PLA 2) is a significant 
aspect of lung diseases that include inflammation (10). 
Annexins (ANXs) are a family of calcium and 
phospholipid cohering proteins with immune-regulatory 
functions in viral infections, lung injury, and 
inflammation. Recent recognition of the role of ANXs in 
modifying IAV infection and host reactions will allow the 
upcoming progress of additional compelling antiviral 
therapies (11). The LST1 gene is constitutively expressed 
in leukocytes and dendritic cells, and it is categorized by 
broad alternative merging and can act as an immune-
regulator while protein expression of LST1 on the cell 
surface of mononuclear cells, and they display an 
inhibitory outcome on lymphocyte proliferation of two 
LST1 proteins (12). New studies have shown the value of 
Fc-mediated antibody effector functions in protection and 
pathogenesis equally for several infectious agents. Fc-
mediated antibody effector operates for the reasonable 
design of secure and efficient vaccines and monoclonal 
antibody rehabilitations against RSV. (13). Thus, it is 
vital to study the FCGR3B gene during the COVID-19 
infection. The novel coronavirus SARS-CoV-2, causing 
the new infectious coronavirus disease-2019 (COVID-
19), is currently spreading rapidly around the world; it has 
been recently declared as a pandemic by WHO. Recent 
clinical observation suggests that patient age, male sex, 
and certain chronic medical conditions (e.g., 
cardiovascular disease, diabetes, COPD) seem to 
represent a risk for the infection of SARS-CoV-2 and 
higher disease severity1. There is currently no biological 
marker known to predict the susceptibility to COVID-19. 
(14). Our results and previous research on these genes 
suggest that DEFA1B, LILRA3, IGLL1, ANXA4, LST1, 
and FCGR3B expression might be up-regulated in 
COVID-19 and other viral respiratory tract infections. 
Consequently, the up-regulation of these genes would 
facilitate infection with COVID-19. We, therefore, 
hypothesize these mentioned genes up-regulation might 
increase the risk of developing severe and fatal COVID-
19. If this hypothesis were to be confirmed, it could lead 
to a conflict regarding the pathogenesis of the different 
viral respiratory tract infections and SARS-CoV-2 
because previously, the up-regulation of these above 
stated are not linked with the pathogenesis of the COVID-
19. Furthermore, these genes are not used in research for 
disease management, drug development, and vaccine 
production of COVID-19. A further aspect that should be 
investigated is the genetic predisposition for an increased 
risk of SARS-CoV-2 infection, which might be due to 
these listed genes or else other human respiratory system-
related genes expression at the time of SARS-CoV-2 and 
VRTIs. DEFA1B, LILRA3, IGLL1, ANXA4, LST1, and 
FCGR3B would be a good candidate for the development 
of novel, host-directed therapeutics to improve COVID-
19 disease management as they are tested for different 
VRTIs disease management in previous studies. 
Summarizing this information, the sensitivity of an 
individual might result from a variation in the gene 
expression profile of these genes and other respiration or 
pulmonary system-related genes during the VRTI plus 
COVID-19 infection. We suggest that patients with 
upregulation of the genes and other pulmonary system 
linked gens are at higher risk for severe COVID-19 
infection and, therefore, patients' gene expression profile 
should be monitored during the infections as some genes’ 
down or up-regulation will impact the pathogenesis and 
mortality rate of the COVID-19. Based on a different 
articles search engine on April 09, 2020, we did not find 
any study that shows the stated genes and other gene 
expression profile which are related to the lungs or 
pulmonary system of the patient at the time of SARS-
CoV-2 and other VRTIs. Therefore, such studies would 
not only provide a suitable approach for the 
understanding and disease management of COVID-19 
and other VRTIs but would also prove valuable in the 
development of the drug and vaccine for the SARS-CoV-
2 or other VRTIs. 
 
 
Table 1. Stated down-regulated DEGs gens in the GSE68310 dataset 
ID Gene Symbol P LogFc 
Up-regulated     
ILMN_1725661 DEFA1B 1.01E-03 1.8148 
ILMN_1661631 LILRA3 9.84E-07 1.7185 
ILMN_2393765 IGLL1 1.07E-04 1.6647 
ILMN_1711408 ANXA4 7.63E-06 1.276 
ILMN_1718936 LST1 9.03E-13 1.2365 
ILMN_1728639 FCGR3B 1.59E-06 1.2244 
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